ERBB2 and interstitial lung disease: For instance, in the case of HER2 ADC, Enhertu, which utilizes the Dxd molecule, interstitial lung disease (ILD)/pneumonitis was reported in 25 out of 184 patients (13.6%) in a global Phase II study involving HER2-positive metastatic breast cancer patients previously treated with trastuzumab emtansine (Modi et al., 2020).